A drug company that is studying a fish-oil drug announced that it will seek U.S. approval after promising clinical trial results. Amarin found that a purified form of ethyl eicosapentaenoic acid, an omega-3 fatty acid known as ethyl EPA, reduced triglyceride levels without increasing "bad" LDL cholesterol. The drug is a potential "blockbuster" that can compete with the likes of Lipitor and Zocor, Adam Feuerstein writes.

Full Story:

Related Summaries